Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 20, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 22, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001104659-26-046835
Filed / recorded
Apr 22, 2026, 8:17 PM UTC
Added to OQRO
Oct 8, 2026, 2:41 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Acurx Pharmaceuticals, Inc.
Issuer CIK
1736243
Ticker
ACXP
Reporting person
David P Luci
Relationship
Director, Officer
Officer title
President and CEO
Security
Stock Option
Table
Derivative (Table II)
Transaction date
Apr 20, 2026
Transaction code
A
Shares / units
37,100
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
37,100
Ownership form
Direct
Amendment
No
Footnotes from the filing
On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
